Syngene International inks R&D agreement with GSK

26 Mar 2018 Evaluate

Syngene International has signed Research and Development (R&D) agreement with GSK, a science-led global healthcare company. The multiyear agreement will focus on accelerating the discovery of new drug candidates using Syngene’s discovery services platforms.

As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas. A team of Syngene scientists will work closely with GSK’s global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world’s most pressing healthcare needs.

Syngene International is India’s largest Contract Research Services Organization providing integrated discovery and development services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides.

Syngene Internation. Share Price

625.80 -1.35 (-0.22%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 625.80
Indegene 477.35
CMS Info Systems 330.40
Sagility 53.81
Smartworks Coworking 443.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×